Bottom line
RYCFX vs FBT: the short answer
RYCFX (Biotechnology Fund) and FBT (First Trust NYSE Arca Biotechnology Index Fund) are both mutual funds.
But RYCFX is far broader, holding 74 positions to 32 for FBT, so beyond the top names it adds exposure FBT doesn't have.
FBT is cheaper at 0.55% vs 2.38% — a difference of $183 a year per $10,000 invested.
Over five years, FBT returned +4.3% a year vs +3.0% for RYCFX.
Updated Nov 19, 2026
RYCFX vs FBT side by side
| RYCFX | FBT | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Guggenheim | First Trust |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 2.38% | 0.55% |
| Annual cost per $10k | $238 | $55 |
| 10-yr cost on $10k (prospectus) | $2,763 | — |
| Max front load | 0% | None |
| 12b-1 fee | 1% | 0% |
| 1-yr return | +28.4% | +24.1% |
| 5-yr return (annualized) | +3.0% | +4.3% |
| 10-yr return (annualized) | +4.8% | +6.3% |
| Best quarter | +28.0% | +27.8% |
| Worst quarter | −22.7% | −22.5% |
| Net assets (fund) | $136.8M | $2.8B |
| Number of holdings | 74 | 32 |
| Portfolio turnover | 75% | 37% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | RYCFX | FBT | Difference |
|---|---|---|---|
| 2025 | +29.4% | +24.1% | +5.3% |
| 2024 | −1.7% | +5.8% | −7.5% |
| 2023 | +5.0% | +2.3% | +2.8% |
| 2022 | −13.9% | −4.6% | −9.3% |
| 2021 | +0.8% | −3.6% | +4.4% |
| 2020 | +20.9% | +12.9% | +7.9% |
| 2019 | +23.8% | +19.8% | +4.0% |
| 2018 | −9.9% | −0.2% | −9.7% |
| 2017 | +28.4% | +37.0% | −8.6% |
| 2016 | −20.3% | −19.6% | −0.7% |
Source: Fund prospectus bar charts
Holdings overlap
10 of RYCFX's top 25 holdings also appear in FBT's top 25.
| Holding | RYCFX | FBT |
|---|---|---|
| Amgen Inc | 5.05% | 2.78% |
| Vertex Pharmaceuticals Inc | 4.32% | 3.07% |
| Alnylam Pharmaceuticals Inc | 2.36% | 2.52% |
| Biogen Inc | 2.13% | 3.37% |
| Natera Inc | 2.12% | 3.79% |
| Illumina Inc | 1.94% | 3.92% |
| United Therapeutics Corp | 1.72% | 2.56% |
| Incyte Corp | 1.62% | 3.18% |
| Neurocrine Biosciences Inc | 1.52% | 3.53% |
| Argenx Se | 1.48% | 3.13% |
Source: SEC Form N-PORT
RYCFX top 10
- Abbvie Inc — 8.17%
- Amgen Inc — 5.05%
- Gilead Sciences Inc — 4.49%
- Vertex Pharmaceuticals Inc — 4.32%
- Regeneron Pharmaceuticals Inc — 2.93%
- Revolution Medicines Inc — 2.48%
- Alnylam Pharmaceuticals Inc — 2.36%
- Beone Medicines Ltd — 2.17%
- Moderna Inc — 2.15%
- Biogen Inc — 2.13%
FBT top 10
- Corcept Therapeutics Inc — 5.60%
- Neogenomics Inc — 5.12%
- Veracyte Inc — 5.10%
- Bruker Corp — 4.32%
- Alkermes Plc — 4.24%
- Illumina Inc — 3.92%
- Krystal Biotech Inc — 3.87%
- Natera Inc — 3.79%
- Axsome Therapeutics Inc — 3.71%
- Neurocrine Biosciences Inc — 3.53%
FAQ
What is the difference between RYCFX and FBT?
Which is cheaper, RYCFX or FBT?
Should I own both RYCFX and FBT?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.